 | • レポートコード：360iR22DE080 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、257ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査報告書では、2021年に279.9億ドルであった世界のバイオ医薬品受託製造市場規模が、2022年に323.7億ドルになり、2027年まで年平均15.92%で成長して679.3億ドルに達すると予測しています。本報告書では、バイオ医薬品受託製造の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（バイオロジクス、バイオシミラー）分析、ソース別（哺乳類、微生物由来生物製剤/非哺乳類製剤）分析、契約種類別（医薬品有効成分（API）、充填＆仕上げ）分析、サービス別（分析・品質管理試験、充填＆仕上げ作業、包装、プロセス開発）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の項目を掲載しています。本書に記載されている企業情報としては、AbbVie, Inc.、AGC Biologics、Ajinomoto Co. Inc.、Binex Co., Ltd.、Boehringer Ingelheim Biopharmaceuticals GmbH、Cambrex Corporation、FUJIFILM Diosynth Biotechnologies U.S.A. Inc、General Electric Co.、INCOG BioPharma Servicesなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のバイオ医薬品受託製造市場規模：製品別 - バイオロジクスの市場規模 - バイオシミラーの市場規模 ・世界のバイオ医薬品受託製造市場規模：ソース別 - 哺乳類由来医薬品受託製造の市場規模 - 微生物由来生物製剤/非哺乳類製剤受託製造の市場規模 ・世界のバイオ医薬品受託製造市場規模：契約種類別 - 医薬品有効成分（API）の市場規模 - 充填・仕上げの市場規模 ・世界のバイオ医薬品受託製造市場規模：サービス別 - 分析・品質管理試験の市場規模 - 充填・仕上げ作業の市場規模 - 包装の市場規模 - プロセス開発の市場規模 ・世界のバイオ医薬品受託製造市場規模：地域別 - 南北アメリカのバイオ医薬品受託製造市場規模 アメリカのバイオ医薬品受託製造市場規模 カナダのバイオ医薬品受託製造市場規模 ブラジルのバイオ医薬品受託製造市場規模 … - アジア太平洋のバイオ医薬品受託製造市場規模 日本のバイオ医薬品受託製造市場規模 中国のバイオ医薬品受託製造市場規模 インドのバイオ医薬品受託製造市場規模 韓国のバイオ医薬品受託製造市場規模 台湾のバイオ医薬品受託製造市場規模 … - ヨーロッパ/中東/アフリカのバイオ医薬品受託製造市場規模 イギリスのバイオ医薬品受託製造市場規模 ドイツのバイオ医薬品受託製造市場規模 フランスのバイオ医薬品受託製造市場規模 ロシアのバイオ医薬品受託製造市場規模 … - その他地域のバイオ医薬品受託製造市場規模 ・競争状況 ・企業情報 |
The Global Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 27.99 billion in 2021 and expected to reach USD 32.37 billion in 2022, and is projected to grow at a CAGR 15.92% to reach USD 67.93 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biopharmaceuticals Contract Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Biologics and Biosimilar.
Based on Source, the market was studied across Mammalian and Microbial-Based Biologics/Non-Mammalia.
Based on Contract Type, the market was studied across Active Pharmaceutical Ingredient (API) and Fill-and-Finished.
Based on Service, the market was studied across Analytical & Quality Control Studies, Fill & Finish Operations, Packaging, and Process Development.
Based on Scale of Operation, the market was studied across Clinical and Commercial.
Based on Therapeutic Applications, the market was studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biopharmaceuticals Contract Manufacturing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopharmaceuticals Contract Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopharmaceuticals Contract Manufacturing Market, including AbbVie, Inc., AGC Biologics, Ajinomoto Co. Inc., Binex Co., Ltd., Boehringer Ingelheim Biopharmaceuticals GmbH, Cambrex Corporation, FUJIFILM Diosynth Biotechnologies U.S.A. Inc, General Electric Co., INCOG BioPharma Services, Inno Bio Ventures Sdn Bhd, JRS Pharma, Lonza AG, Merck KGaA, Pressure BioSciences, ProBioGen AG, Rentschler Biotechnologie GmbH, Samsung Biologics Co. Ltd., Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., and WuXi Biologics, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biopharmaceuticals Contract Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopharmaceuticals Contract Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopharmaceuticals Contract Manufacturing Market?
4. What is the competitive strategic window for opportunities in the Global Biopharmaceuticals Contract Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the Global Biopharmaceuticals Contract Manufacturing Market?
6. What is the market share of the leading vendors in the Global Biopharmaceuticals Contract Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the Global Biopharmaceuticals Contract Manufacturing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising outsourcing by biopharmaceutical companies
5.1.1.2. Increasing Number of CMOs and Rising Investments in Advanced Manufacturing Technologies
5.1.1.3. Growing demand for biologics globally
5.1.2. Restraints
5.1.2.1. High cost of setting up a production facility for biopharmaceuticals
5.1.3. Opportunities
5.1.3.1. Increasing investments in biopharmaceutical R&D and manufacturing
5.1.3.2. Growing focus on speciality drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements for CMOs
5.2. Cumulative Impact of COVID-19
6. Biopharmaceuticals Contract Manufacturing Market, by Product
6.1. Introduction
6.2. Biologics
6.3. Biosimilar
7. Biopharmaceuticals Contract Manufacturing Market, by Source
7.1. Introduction
7.2. Mammalian
7.3. Microbial-Based Biologics/Non-Mammalia
8. Biopharmaceuticals Contract Manufacturing Market, by Contract Type
8.1. Introduction
8.2. Active Pharmaceutical Ingredient (API)
8.3. Fill-and-Finished
9. Biopharmaceuticals Contract Manufacturing Market, by Service
9.1. Introduction
9.2. Analytical & Quality Control Studies
9.3. Fill & Finish Operations
9.4. Packaging
9.5. Process Development
10. Biopharmaceuticals Contract Manufacturing Market, by Scale of Operation
10.1. Introduction
10.2. Clinical
10.3. Commercial
11. Biopharmaceuticals Contract Manufacturing Market, by Therapeutic Applications
11.1. Introduction
11.2. Cardiovascular Diseases
11.3. Infectious Disease
11.4. Neurology
11.5. Oncology
11.6. Ophthalmology
11.7. Respiratory Disorder
12. Americas Biopharmaceuticals Contract Manufacturing Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AbbVie, Inc.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. AGC Biologics
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Ajinomoto Co. Inc.
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Binex Co., Ltd.
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Boehringer Ingelheim Biopharmaceuticals GmbH
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Cambrex Corporation
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. FUJIFILM Diosynth Biotechnologies U.S.A. Inc
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. General Electric Co.
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. INCOG BioPharma Services
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Inno Bio Ventures Sdn Bhd
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. JRS Pharma
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. Lonza AG
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Merck KGaA
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Pressure BioSciences
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. ProBioGen AG
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Rentschler Biotechnologie GmbH
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Samsung Biologics Co. Ltd.
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. Thermo Fisher Scientific, Inc.
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Toyobo Co. Ltd.
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. WuXi Biologics, Inc.
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing